You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Clinical Connect: Addressing Residual Symptoms and Preventing Relapse in Major Depressive Disorder

  • Authors: Gregory W. Mattingly, MD
  • CME / ABIM MOC / CE Released: 9/27/2022
  • Valid for credit through: 9/27/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for advanced practice providers (nurses, nurse practitioners, and physician assistants) in primary care and psychiatry, psychiatrists, primary care physicians, obstetricians and gynecologists, pharmacists, and other clinicians who treat patients with MDD.

The goal of this activity is that learners will be better able to recognize residual symptoms in MDD care, better predict the risk of relapse in patients with MDD, and adjust treatments appropriately.

Upon completion of this activity, participants will:

  • Have greater competence related to
    • Assessing the impact of residual MDD symptoms on psychosocial functioning using measurement-based care principles 
    • Selecting treatment options for residual symptoms that may lead to relapse
    • Timely tailoring/switch of therapeutic interventions for patients with residual symptoms of MDD
  • Demonstrate improved performance associated with
    • Assessing the impact of residual MDD symptoms on psychosocial functioning using measurement-based care principles 
    • Assessing the risk of relapse for patients experiencing significant residual symptoms
    • Timely tailoring/switch of therapeutic interventions for patients with residual symptoms of MDD


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Gregory W. Mattingly, MD

    Associate Clinical Professor
    Washington University School of Medicine
    President, Midwest Research Group
    President Elect, APSARD- American Professional Society for ADHD and Related Disorders
    St. Louis, Missouri

    Disclosures

    Gregory W. Mattingly, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie; Acadia; Alkermes; Axsome; Corium; Eisai; Intracellular; Ironshore; Janssen; Lundbeck; Neos; Neurocrine; Noven; Otsuka; Redax; Rhodes; Roche; Sage; Sunovion; Supernus; Takeda; Teva; Trispharma
    Research funding from: AbbVie; Alkermes; Corium; Eisai; Intracellular; Ironshore; Janssen; Lundbeck; Neurocrine; Noven; Otsuka; Sunovion; Supernus; Takeda; Trispharma
    Contracted researcher for: AbbVie; Acadia; Akili; Alkermes; Axsome; Boehringer Ingelheim; Emalex; Idorsia; Janssen; Karuna; Lumos Labs; Medgenics; NLS-1 Pharma AG; Redax; Relmada; Roche; Sage; Sirtsei; Sunovion; Supernus; Takeda; Teva

Editors

  • Clinton W. Wright, PharmD, BCPP

    Medical Education Director, Medscape, LLC 

    Disclosures

    Clinton W. Wright, PharmD, BCPP, has no relevant financial relationships.

  • Renata Feldman, PharmD

    Scientific Content Manager, Medscape, LLC 

    Disclosures

    Renata Feldman, PharmD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-22-314-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Clinical Connect: Addressing Residual Symptoms and Preventing Relapse in Major Depressive Disorder

Authors: Gregory W. Mattingly, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 9/27/2022

Valid for credit through: 9/27/2023

processing....

Educational Impact Challenge

The goal of this activity is that learners will be better able to recognize residual symptoms in MDD care, better predict the risk of relapse in patients with MDD, and adjust treatments appropriately.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print